

Bcl10 (h): 293T Lysate: sc-116437

BACKGROUND

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene and, like E10, it contains an N-terminal caspase recruitment domain (CARD). Expression of Bcl10 has been shown to induce NFκB activation in a NIK-dependent pathway. Research indicates that the CARD domain is essential for this activation, although in a separate study, Bcl10 by itself did not induce JNK or NFκB activation. Overexpression of Bcl10 has been shown to induce apoptosis in a manner dependent on CARD-mediated oligomerization. Bcl10 has also been shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.

REFERENCES

1. Ye, H., et al. 2000. Bcl10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. *Am. J. Pathol.* 157: 1147-1154.
2. Ruland, J., et al. 2001. Bcl10 is a positive regulator of antigen receptor-induced activation of NFκB and neural tube closure. *Cell* 104: 33-42.
3. Lucas, P.C., et al. 2001. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NFκB signaling pathway. *J. Biol. Chem.* 276: 19012-19019.
4. Yui, D., et al. 2001. Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling. *Oncogene* 20: 4317-4323.
5. Thome, M., et al. 2002. Bcl10. *Curr. Biol.* 12: R45.
6. Zhou, H. et al. 2004. Bcl10 activates the NFκB pathway through ubiquitination of NEMO. *Nature* 427: 167-171.
7. Fischer, K.D., et al. 2004. New roles for Bcl10 in B cell development and LPS response. *Trends. Immunol.* 25: 113-116.
8. Scharschmidt, E. et al. 2004. Degradation of Bcl10 induced by T cell activation negatively regulates NFκB signaling. *Mol. Cell. Biol.* 24: 3860-3873.
9. Liu, Y. et al. 2004. Bcl10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2. *J. Biol. Chem.* 279: 37436-37444.

CHROMOSOMAL LOCATION

Genetic locus: BCL10 (human) mapping to 1P22.3.

PRODUCT

Bcl10 (h): 293T Lysate represents a lysate of human Bcl10 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

APPLICATIONS

Bcl10 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive Bcl10 antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

Bcl10 (A-6): sc-13153 is recommended as a positive control antibody for Western Blot analysis of enhanced human Bcl10 expression in Bcl10 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™
Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



Bcl10 (A-6): sc-13153. Western blot analysis of Bcl10 expression in non-transfected: sc-117752 (A) and human Bcl10 transfected: sc-116437 (B) 293T whole cell lysates.



Bcl10 (331.3): sc-5273. Western blot analysis of Bcl10 expression in non-transfected: sc-117752 (A) and human Bcl10 transfected: sc-116437 (B) 293T whole cell lysates.

RESEARCH USE

For research use only, not for use in diagnostic procedures.